[
    [
        {
            "time": "2019-09-30",
            "original_text": "WeWork IPO was a Failure – These 2 IPO Stocks are Surging",
            "features": {
                "keywords": [
                    "WeWork",
                    "IPO",
                    "Failure",
                    "Surging"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "real estate",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "WeWork IPO was a Failure – These 2 IPO Stocks are Surging",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-10-22",
            "original_text": "The Good, Bad, and Ugly for Biogen Stock",
            "features": {
                "keywords": [
                    "Good",
                    "Bad",
                    "Ugly",
                    "Biogen"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "The Good, Bad, and Ugly for Biogen Stock",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-11-05",
            "original_text": "Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss",
            "features": {
                "keywords": [
                    "Agios",
                    "Q3",
                    "Loss",
                    "Narrower",
                    "Revenues",
                    "Miss"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-11-14",
            "original_text": "UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "2019",
                    "sales",
                    "outlook",
                    "new drugs",
                    "excel"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]